China Stock Traders Most Defensive in Years on Growth Doubts
(Bloomberg) -- China's army of stock investors are taking cover.
They've been loading up on companies with earnings that are less reliant on economic growth, and ditching banks and oil producers. Gauges of consumer staples and health-care shares have surged to the highest levels relative to the CSI 300 Index since at least 2013 in recent days, while a measure of financial companies is near the lowest since November 2015. A crackdown on leveraged trades by regulators has only made investors more defensive.
"People are turning their eyes to booze and drugs amid waning growth momentum in the economy," said Hao Hong, Bocom International Holdings Co.'s chief strategist in Hong Kong. "Low-beta defensive plays outperform in a risk-averse market as the companies provide better earnings growth and cash flow. The rally has a further leg to go, at least in the second quarter."
Recent data appear to support such caution. Manufacturing gauges fell in April, signaling headwinds for an economy that accelerated in the past two quarters. Iron ore, considered a proxy for the nation's infrastructure spending, entered a bear market last month amid a near-record mountain of stockpiles. The dour sentiment helped send the CSI 300 to its lowest level since Feb. 17 on Tuesday.
Liquor makers have been among the biggest beneficiaries of the shift to so-called defensive shares. The consumer staples gauge has rallied 15 percent this year, and closed at its highest level since June 2015 on Thursday. Luzhou Laojiao Co. and Wuliangye Yibin Co. have jumped at least 30 percent to lead gains, followed by Yonghui Superstores Co. Utilities and health-care shares have climbed more than 8 percent, compared with the CSI 300's 3.1 percent advance.
There are signs of caution filtering into these industry groups as valuations swell. The consumer staples index slumped 3.1 percent in the two trading days through Tuesday, while the health-care index retreated 1.8 percent. Both measures trade at least 12 percent above their average multiple over the past five years, using price to estimated earnings. The consumer staples index snapped its two-day loss Wednesday with 0.5 percent rise, the biggest gainer on the CSI 300 Index which slipped 0.4 percent at close. Health-care plays were little changed.
Crowded Trade
For Credit Suisse Group AG's Hong Kong-based strategist Chen Li, sectors such as liquor and home appliances are getting crowded.
"I'm concerned; these stocks have had some decent gains, but it's not going to be a money-making situation for all," said Chen. "With everyone flocking into such investments, there's a risk of a selling stampede should someone start to pull out and trigger a price correction."
Still, Hengsheng Asset Management Co. says the government's focus on reducing risk in financial markets will add to investor perception that consumer and health-care shares offer safe havens.
China's regulators have unveiled a raft of measures over the past month to curb leverage, boost transparency and prevent excessive speculation. In one sign that the reform drive has further to run, President Xi Jinping gave it a stamp of approval by presiding over a rare meeting with top financial regulators last week. The crackdown spurred a selloff in the broader market, with gauges of energy, financial and industrial companies being hardest hit over the course of April.
"Risk appetite drops on tighter scrutiny," said Dai Ming, fund manager at Hengsheng Asset Management in Shanghai. "Investors will still need something to trade on after the crackdown on speculative trades, and their choices naturally go to steady bets like consumer stocks."
--With assistance from Ryan Lovdahl
To contact Bloomberg News staff for this story: Amanda Wang in Shanghai at twang234@bloomberg.net.
To contact the editors responsible for this story: Richard Frost at rfrost4@bloomberg.net, Sarah McDonald
With assistance from Amanda Wang
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
-
You May Inherit The Business. You Must Earn Its Credibility.
Succession tests the founder's ability to share authority as much as it tests the next generation's readiness to assume it.